Impact of HER2-targeting antibody drug conjugates in treatment strategies for patients with breast cancer
Antibody drug conjugates (ADCs) are novel drugs that exert specific cytotoxicity against breast cancer. Although ADCs such as trastuzumab emtansine and trastuzumab deruxtecan have significantly improved survival for patients with breast cancer expressing HER2, there is still controversy over options...
Salvato in:
| Autori principali: | , |
|---|---|
| Natura: | Artigo |
| Lingua: | Inglês |
| Pubblicazione: |
Elsevier
2025-02-01
|
| Serie: | Heliyon |
| Soggetti: | |
| Accesso online: | http://www.sciencedirect.com/science/article/pii/S2405844024176219 |
| Tags: |
Nessun Tag, puoi essere il primo ad aggiungerne!!
|